.
Angewandte
Communications
DOI: 10.1002/anie.201206863
Natural Product Synthesis
Total Synthesis of (À)-Lycoposerramine-S**
Naoaki Shimada, Yuzo Abe, Satoshi Yokoshima, and Tohru Fukuyama*
Lycopodium alkaloids have attracted the attention of syn-
thetic chemists because of their intriguing structural features
and the remarkable bioactivities.[1] Among them is (À)-
lycoposerramine-S (1; Figure 1), which was isolated from
Lycopodium serratum by Takayama
achieved by alkylation of a nosyl amide and radical cycliza-
tion, respectively. The requisite precursor 2 would be derived
from the ketoester 3. The bicyclic system of 3 could in turn be
constructed by an intramolecular cycloaddition of the azo-
methine ylide 4.[4]
Our synthesis commenced with preparation of the pre-
cursor of the azomethine ylide (Scheme 2). Reaction of the
alkyl iodide 5[5] with an anion derived from the terminal
and co-workers in 2002[2] and has
a unique structure including a highly
fused tetracyclic skeleton with two
nitrogen atoms and one quaternary
carbon center. Although synthetic
studies of (À)-lycoposerramine-S
were reported by Elliott and co-work-
Figure 1. Structure of
lycoposerramine-S.
ers,[3] its total synthesis has not been
reported to date. Although the bio-
logical activity of this molecule has
not yet been determined, we were interested in exploring this
unique molecule and its derivatives for drug discovery.
Herein, we report the first total synthesis of (À)-lycoposerr-
amine-S (1). Key to the straightforward construction of the
tetracyclic skeleton was the unexpected stereoselectivity in
the intramolecular cycloaddition of an azomethine ylide.
Our retrosynthesis is shown in Scheme 1. Formation of the
nine-membered ring and the cyclopentane ring could be
Scheme 2. Preparation of a precursor for the azomethine ylide.
a) nBuLi, HCC(CH2)3OTBS (6), THF/DMPU, À788C to RT, 87%;
b) [Cp2ZrCl2], DIBAL, THF, 08C to RT; I2, À788C, 87%; c) nBuLi, Et2O,
À788C; 9, À788C, 66%; d) TPAP, NMO, 4ꢀ M.S., CH2Cl2, RT, 75%.
Cp=cyclopentadienyl, DIBAL=diisobutylaluminum hydride,
DMPU=N,N’-dimethylpropyleneurea, M.S.=molecular sieves,
NMO=N-methylmorpholine N-oxide, TBS=tert-butyldimethylsilyl,
TPAP=tetrapropylammonium perruthenate.
alkyne 6 afforded the alkyne 7, which was subjected to
hydrozirconation and subsequent addition of iodine to give
the alkenyl iodide 8.[6] Halogen–lithium exchange of 8
generated the corresponding alkenyllithium species, which
was reacted with the known lactone 9[7] to afford 10.
Subsequent oxidation of the hydroxy group in 10 furnished
the ketoaldehyde 11, which was used for the cycloaddition of
the azomethine ylide.
Treatment of 11 with N-benzylglycine ethyl ester in
refluxing toluene formed an azomethine ylide, which under-
went cycloaddition to afford the product as a 4:3 mixture of
two diastereomers which differed in the relative configuration
at C15. This result indicated that the distant methyl group on
C15 did not control the facial selectivity of the cycloaddition.
Therefore we decided to employ chiral amino esters as
reagents for the cycloaddition. Using (5S,6R)-5,6-diphenyl-
morpholin-2-one,[8] the cycloaddition proceeded stereoselec-
tively, albeit in low yield. After intensive screening of chiral
amino esters, we found that the morpholinone 12 gave the
best selectivity and yield.[9] Thus, heating 11 with 12 in toluene
furnished the adduct 13 in 86% yield as a single isomer
Scheme 1. Retrosynthesis.
[*] N. Shimada, Dr. Y. Abe, Dr. S. Yokoshima,[+] Prof. T. Fukuyama
Graduate School of Pharmaceutical Sciences, University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 (Japan)
E-mail: fukuyama@mol.f.u-tokyo.ac.jp
[+] Current address: Graduate School of Pharmaceutical Sciences,
Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601 (Japan)
[**] We thank Prof. Hiromitsu Takayama at Chiba University for helpful
discussions. This work was financially supported by Grants-in-Aid
for Scientific Research (20002004, 22590002) from the Japan
Society for the Promotion of Science (JSPS), the Research
Foundation for Pharmaceutical Sciences, the Mochida Memorial
Foundation for Medical and Pharmaceutical Research, and the
Uehara Memorial Foundation.
Supporting information for this article is available on the WWW
11824
ꢀ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Angew. Chem. Int. Ed. 2012, 51, 11824 –11826